We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Moving Closer to a Shingles Vaccine, Likely Competitor to Zostavax
GSK Moving Closer to a Shingles Vaccine, Likely Competitor to Zostavax
August 23, 2010
GlaxoSmithKline (GSK) is beginning Phase III trials of its herpes zoster vaccine, a treatment that would likely compete against Merck’s Zostavax.